VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a nonbinding letter of intent (LOI) with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology (LFT) for detecting NETosis, a process associated with inflammation. The collaboration will initially focus on evaluating a finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings. The announcement, detailed in a recent press release, signals a step toward decentralized testing for a condition that remains a critical challenge in resource-constrained regions.
The LOI is nonbinding, meaning no obligation to proceed, but it outlines a framework for collaboration. Missionpharma, which supplies healthcare products to United Nations agencies, government health ministries and other institutions, could support low-cost manufacturing, clinical studies and distribution. Volition believes this could accelerate access to affordable diagnostic tools where early identification and management of neonatal sepsis are crucial. The prototype LFT measures circulating nucleosomes and neutrophil extracellular traps as potential early indicators of hyperinflammation. The technology follows Volition’s recent announcement that results from its lateral flow prototype demonstrated high correlation with its established automated Nu.Q NETs test in critically ill sepsis patients. This correlation is significant because it suggests the simpler, point-of-care LFT could perform comparably to laboratory-based testing, enabling use in settings without centralized labs.
Neonatal sepsis is a leading cause of infant mortality globally, particularly in low- and middle-income countries where access to timely diagnosis is limited. A finger-prick test that can be run without sophisticated equipment could enable earlier intervention and reduce deaths. The collaboration aligns with global health efforts to improve maternal and child health. For investors, the LOI represents a potential path to commercializing Volition’s NETosis technology beyond centralized laboratory testing, though the nonbinding nature means uncertainty remains. For the diagnostics industry, it highlights a trend toward point-of-care solutions for inflammation and infection. The full press release can be viewed at https://nnw.fm/9AltW. More information about Volition is available at Volition's website. The announcement was distributed via NetworkNewsWire, a specialized communications platform. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which provides services such as InvestorWire for wire distribution and editorial syndication to 5,000+ outlets. The company also offers press release enhancement and social media distribution. For full terms, see the https://www.NetworkNewsWire.com/Disclaimer.
